Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 1673 entries
Sorted by: Best Match Show Resources per page
Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria.

Case reports in hematology

Ninomiya H, Obara N, Niiori-Onishi A, Yokoyama Y, Sakata-Yanagimoto M, Hasegawa Y, Chiba S.
PMID: 26124968
Case Rep Hematol. 2015;2015:673195. doi: 10.1155/2015/673195. Epub 2015 Jun 01.

Chronic kidney disease (CKD) is one of the major manifestations of paroxysmal nocturnal hemoglobinuria (PNH). CKD in PNH is induced mainly by intravascular hemolysis of PNH-affected red blood cells (RBC) missing the glycosylphosphatidylinositol-anchored proteins with complement-regulatory activities, CD55 and...

Cite
Ninomiya H, Obara N, Niiori-Onishi A, et al. Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria. Case Rep Hematol. 2015;2015:673195doi: 10.1155/2015/673195.
Ninomiya, H., Obara, N., Niiori-Onishi, A., Yokoyama, Y., Sakata-Yanagimoto, M., Hasegawa, Y., & Chiba, S. (2015). Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria. Case reports in hematology, 2015673195. https://doi.org/10.1155/2015/673195
Ninomiya, Haruhiko, et al. "Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria." Case reports in hematology vol. 2015 (2015): 673195. doi: https://doi.org/10.1155/2015/673195
Ninomiya H, Obara N, Niiori-Onishi A, Yokoyama Y, Sakata-Yanagimoto M, Hasegawa Y, Chiba S. Improvement of Renal Function by Long-Term Sustained Eculizumab Treatment in a Patient with Paroxysmal Nocturnal Hemoglobinuria. Case Rep Hematol. 2015;2015:673195. doi: 10.1155/2015/673195. Epub 2015 Jun 01. PMID: 26124968; PMCID: PMC4466353.
Copy Download .nbib Format: NLM
Mold Pectinase Modified with Dialdehyde Derivatives of Dextran and Cellulose.

Bioscience, biotechnology, and biochemistry

Kobayashi M, Chiba Y, Funane K, Ohya S, Kato Y.
PMID: 27281140
Biosci Biotechnol Biochem. 1996 Jan;60(5):794-7. doi: 10.1271/bbb.60.794.

Chemical modification of mold pectinase with dextran- and cellulose-dialdehydes was examined to improve the enzyme characteristics. The modified pectinase with dextran-dialdehyde retained about 50% of the original activity, and more than 80% of the total amino groups were modified....

Cite
Kobayashi M, Chiba Y, Funane K, et al. Mold Pectinase Modified with Dialdehyde Derivatives of Dextran and Cellulose. Biosci Biotechnol Biochem. 1996;60(5):794-7doi: 10.1271/bbb.60.794.
Kobayashi, M., Chiba, Y., Funane, K., Ohya, S., & Kato, Y. (1996). Mold Pectinase Modified with Dialdehyde Derivatives of Dextran and Cellulose. Bioscience, biotechnology, and biochemistry, 60(5), 794-7. https://doi.org/10.1271/bbb.60.794
Kobayashi, M, et al. "Mold Pectinase Modified with Dialdehyde Derivatives of Dextran and Cellulose." Bioscience, biotechnology, and biochemistry vol. 60,5 (1996): 794-7. doi: https://doi.org/10.1271/bbb.60.794
Kobayashi M, Chiba Y, Funane K, Ohya S, Kato Y. Mold Pectinase Modified with Dialdehyde Derivatives of Dextran and Cellulose. Biosci Biotechnol Biochem. 1996 Jan;60(5):794-7. doi: 10.1271/bbb.60.794. PMID: 27281140.
Copy Download .nbib Format: NLM
Late-onset acetaminophen-induced allergic hepatitis with progression to chronicity.

Hepatology research : the official journal of the Japan Society of Hepatology

Mishima-Iwai M, Takahashi K, Yokode M, Kimura Y, Sawai Y, Ueda Y, Chiba T.
PMID: 25088083
Hepatol Res. 2015 Jul;45(7):814-7. doi: 10.1111/hepr.12399. Epub 2014 Sep 02.

Acetaminophen (paracetamol), a widely used antipyretic/analgesic, is a well-known agent causing acute hepatic injury. Whereas most cases are caused by its intrinsic hepatotoxicity, idiosyncratic hepatitis by the allergic mechanism is extremely rare. We herein report a case of late-onset...

Cite
Mishima-Iwai M, Takahashi K, Yokode M, et al. Late-onset acetaminophen-induced allergic hepatitis with progression to chronicity. Hepatol Res. 2014;45(7):814-7doi: 10.1111/hepr.12399.
Mishima-Iwai, M., Takahashi, K., Yokode, M., Kimura, Y., Sawai, Y., Ueda, Y., & Chiba, T. (2015). Late-onset acetaminophen-induced allergic hepatitis with progression to chronicity. Hepatology research : the official journal of the Japan Society of Hepatology, 45(7), 814-7. https://doi.org/10.1111/hepr.12399
Mishima-Iwai, Masako, et al. "Late-onset acetaminophen-induced allergic hepatitis with progression to chronicity." Hepatology research : the official journal of the Japan Society of Hepatology vol. 45,7 (2015): 814-7. doi: https://doi.org/10.1111/hepr.12399
Mishima-Iwai M, Takahashi K, Yokode M, Kimura Y, Sawai Y, Ueda Y, Chiba T. Late-onset acetaminophen-induced allergic hepatitis with progression to chronicity. Hepatol Res. 2015 Jul;45(7):814-7. doi: 10.1111/hepr.12399. Epub 2014 Sep 02. PMID: 25088083.
Copy Download .nbib Format: NLM
Kidney Regeneration: Lessons from Development.

Current pathobiology reports

Chiba T, Hukriede N, de Caestecker MP.
PMID: 26120499
Curr Pathobiol Rep. 2015 Mar;3(1):67-79. doi: 10.1007/s40139-015-0069-z.

A number of genes involved in kidney development are reactivated in the adult after acute kidney injury (AKI). This has led to the belief that tissue repair mechanisms recapitulate pathways involved in embryonic development after AKI. We will discuss...

Cite
Chiba T, Hukriede N, de Caestecker MP. Kidney Regeneration: Lessons from Development. Curr Pathobiol Rep. 2015;3(1):67-79doi: 10.1007/s40139-015-0069-z.
Chiba, T., Hukriede, N., & de Caestecker, M. P. (2015). Kidney Regeneration: Lessons from Development. Current pathobiology reports, 3(1), 67-79. https://doi.org/10.1007/s40139-015-0069-z
Chiba, Takuto, et al. "Kidney Regeneration: Lessons from Development." Current pathobiology reports vol. 3,1 (2015): 67-79. doi: https://doi.org/10.1007/s40139-015-0069-z
Chiba T, Hukriede N, de Caestecker MP. Kidney Regeneration: Lessons from Development. Curr Pathobiol Rep. 2015 Mar;3(1):67-79. doi: 10.1007/s40139-015-0069-z. PMID: 26120499; PMCID: PMC4477536.
Copy Download .nbib Format: NLM
Multiplex cytokine analysis of Werner syndrome.

Intractable & rare diseases research

Goto M, Hayata K, Chiba J, Matsuura M, Iwaki-Egawa S, Watanabe Y.
PMID: 26668779
Intractable Rare Dis Res. 2015 Nov;4(4):190-7. doi: 10.5582/irdr.2015.01035.

We reported a minor inflammation-driven ageing (inflammageing) assessed by highly sensitive CRP (hsCRP) in normal individuals and patients with Werner syndrome (WS), followed by an ageing associated Th2-biased cytokine change in normal ageing in the previous papers. To further...

Cite
Goto M, Hayata K, Chiba J, et al. Multiplex cytokine analysis of Werner syndrome. Intractable Rare Dis Res. 2015;4(4):190-7doi: 10.5582/irdr.2015.01035.
Goto, M., Hayata, K., Chiba, J., Matsuura, M., Iwaki-Egawa, S., & Watanabe, Y. (2015). Multiplex cytokine analysis of Werner syndrome. Intractable & rare diseases research, 4(4), 190-7. https://doi.org/10.5582/irdr.2015.01035
Goto, Makoto, et al. "Multiplex cytokine analysis of Werner syndrome." Intractable & rare diseases research vol. 4,4 (2015): 190-7. doi: https://doi.org/10.5582/irdr.2015.01035
Goto M, Hayata K, Chiba J, Matsuura M, Iwaki-Egawa S, Watanabe Y. Multiplex cytokine analysis of Werner syndrome. Intractable Rare Dis Res. 2015 Nov;4(4):190-7. doi: 10.5582/irdr.2015.01035. PMID: 26668779; PMCID: PMC4660860.
Copy Download .nbib Format: NLM
Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma.

Hepatology international

Ogasawara S, Kanai F, Ooka Y, Motoyama T, Suzuki E, Tawada A, Chiba T, Yokosuka O.
PMID: 26201804
Hepatol Int. 2013 Jun;7(2):703-13. doi: 10.1007/s12072-013-9425-4. Epub 2013 Feb 12.

PURPOSE: Sorafenib induces early vascularity reduction in patients with hepatocellular carcinoma (HCC). We sought to identify differences in radiological assessment approaches and to evaluate their usefulness for the prediction of the initial response to sorafenib.METHODS: Forty-eight patients with advanced...

Cite
Ogasawara S, Kanai F, Ooka Y, et al. Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma. Hepatol Int. 2013;7(2):703-13doi: 10.1007/s12072-013-9425-4.
Ogasawara, S., Kanai, F., Ooka, Y., Motoyama, T., Suzuki, E., Tawada, A., Chiba, T., & Yokosuka, O. (2013). Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma. Hepatology international, 7(2), 703-13. https://doi.org/10.1007/s12072-013-9425-4
Ogasawara, Sadahisa, et al. "Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma." Hepatology international vol. 7,2 (2013): 703-13. doi: https://doi.org/10.1007/s12072-013-9425-4
Ogasawara S, Kanai F, Ooka Y, Motoyama T, Suzuki E, Tawada A, Chiba T, Yokosuka O. Initial response to sorafenib by using enhancement criteria in patients with hepatocellular carcinoma. Hepatol Int. 2013 Jun;7(2):703-13. doi: 10.1007/s12072-013-9425-4. Epub 2013 Feb 12. PMID: 26201804.
Copy Download .nbib Format: NLM
Oxidative and Hydrolytic Stability of Synthetic Diacyl Glyceryl Ether.

Bioscience, biotechnology, and biochemistry

Endo Y, Chiba T, Fujimoto K.
PMID: 27299396
Biosci Biotechnol Biochem. 1996 Jan;60(2):216-9. doi: 10.1271/bbb.60.216.

Diacyl glyceryl ethers (DGEs) as present in marine animals were chemically synthesized and then were assessed for their oxidative and hydrolytic stabilities. CDD and CEE were easily autoxidized but not COO. The autoxidation rate of DGEs followed the unsaturation...

Cite
Endo Y, Chiba T, Fujimoto K. Oxidative and Hydrolytic Stability of Synthetic Diacyl Glyceryl Ether. Biosci Biotechnol Biochem. 1996;60(2):216-9doi: 10.1271/bbb.60.216.
Endo, Y., Chiba, T., & Fujimoto, K. (1996). Oxidative and Hydrolytic Stability of Synthetic Diacyl Glyceryl Ether. Bioscience, biotechnology, and biochemistry, 60(2), 216-9. https://doi.org/10.1271/bbb.60.216
Endo, Y, et al. "Oxidative and Hydrolytic Stability of Synthetic Diacyl Glyceryl Ether." Bioscience, biotechnology, and biochemistry vol. 60,2 (1996): 216-9. doi: https://doi.org/10.1271/bbb.60.216
Endo Y, Chiba T, Fujimoto K. Oxidative and Hydrolytic Stability of Synthetic Diacyl Glyceryl Ether. Biosci Biotechnol Biochem. 1996 Jan;60(2):216-9. doi: 10.1271/bbb.60.216. PMID: 27299396.
Copy Download .nbib Format: NLM
Successful interventional treatment for arterioportal fistula caused by radiofrequency ablation for hepatocellular carcinoma.

Case reports in oncology

Kanogawa N, Chiba T, Ogasawara S, Ooka Y, Suzuki E, Motoyama T, Saito T, Sekimoto T, Tawada A, Maruyama H, Yoshikawa M, Yokosuka O.
PMID: 25685134
Case Rep Oncol. 2014 Dec 19;7(3):833-9. doi: 10.1159/000370305. eCollection 2014.

Radiofrequency ablation (RFA) is commonly used as a treatment for small hepatocellular carcinoma (HCC). Although several complications such as intraperitoneal bleeding are often observed after RFA, hepatic arterioportal fistula (APF) is a less frequently occurring complication. In this study,...

Cite
Kanogawa N, Chiba T, Ogasawara S, et al. Successful interventional treatment for arterioportal fistula caused by radiofrequency ablation for hepatocellular carcinoma. Case Rep Oncol. 2014;7(3):833-9doi: 10.1159/000370305.
Kanogawa, N., Chiba, T., Ogasawara, S., Ooka, Y., Suzuki, E., Motoyama, T., Saito, T., Sekimoto, T., Tawada, A., Maruyama, H., Yoshikawa, M., & Yokosuka, O. (2014). Successful interventional treatment for arterioportal fistula caused by radiofrequency ablation for hepatocellular carcinoma. Case reports in oncology, 7(3), 833-9. https://doi.org/10.1159/000370305
Kanogawa, Naoya, et al. "Successful interventional treatment for arterioportal fistula caused by radiofrequency ablation for hepatocellular carcinoma." Case reports in oncology vol. 7,3 (2014): 833-9. doi: https://doi.org/10.1159/000370305
Kanogawa N, Chiba T, Ogasawara S, Ooka Y, Suzuki E, Motoyama T, Saito T, Sekimoto T, Tawada A, Maruyama H, Yoshikawa M, Yokosuka O. Successful interventional treatment for arterioportal fistula caused by radiofrequency ablation for hepatocellular carcinoma. Case Rep Oncol. 2014 Dec 19;7(3):833-9. doi: 10.1159/000370305. eCollection 2014. PMID: 25685134; PMCID: PMC4307006.
Copy Download .nbib Format: NLM
Mixed acinar-endocrine carcinoma of the pancreas treated with S-1.

Clinical journal of gastroenterology

Kanemasa Y, Kamisawa T, Tabata T, Kuruma S, Iwasaki S, Chiba K, Kuwata G, Fujiwara T, Egashira H, Koizumi K, Fujiwara J, Arakawa T, Momma K, Rokutan H, Horiguchi S, Hishima T.
PMID: 26182137
Clin J Gastroenterol. 2013 Dec;6(6):459-64. doi: 10.1007/s12328-013-0416-8. Epub 2013 Sep 05.

The case of a 63-year-old male with a large mass in the pancreatic tail and multiple liver metastases, diagnosed as acinar cell carcinoma of the pancreas with a few scattered endocrine cells by liver biopsy is presented. The S-1...

Cite
Kanemasa Y, Kamisawa T, Tabata T, et al. Mixed acinar-endocrine carcinoma of the pancreas treated with S-1. Clin J Gastroenterol. 2013;6(6):459-64doi: 10.1007/s12328-013-0416-8.
Kanemasa, Y., Kamisawa, T., Tabata, T., Kuruma, S., Iwasaki, S., Chiba, K., Kuwata, G., Fujiwara, T., Egashira, H., Koizumi, K., Fujiwara, J., Arakawa, T., Momma, K., Rokutan, H., Horiguchi, S., & Hishima, T. (2013). Mixed acinar-endocrine carcinoma of the pancreas treated with S-1. Clinical journal of gastroenterology, 6(6), 459-64. https://doi.org/10.1007/s12328-013-0416-8
Kanemasa, Yusuke, et al. "Mixed acinar-endocrine carcinoma of the pancreas treated with S-1." Clinical journal of gastroenterology vol. 6,6 (2013): 459-64. doi: https://doi.org/10.1007/s12328-013-0416-8
Kanemasa Y, Kamisawa T, Tabata T, Kuruma S, Iwasaki S, Chiba K, Kuwata G, Fujiwara T, Egashira H, Koizumi K, Fujiwara J, Arakawa T, Momma K, Rokutan H, Horiguchi S, Hishima T. Mixed acinar-endocrine carcinoma of the pancreas treated with S-1. Clin J Gastroenterol. 2013 Dec;6(6):459-64. doi: 10.1007/s12328-013-0416-8. Epub 2013 Sep 05. PMID: 26182137.
Copy Download .nbib Format: NLM
SPANG: a SPARQL client supporting generation and reuse of queries for distributed RDF databases.

BMC bioinformatics

Chiba H, Uchiyama I.
PMID: 28178937
BMC Bioinformatics. 2017 Feb 08;18(1):93. doi: 10.1186/s12859-017-1531-1.

BACKGROUND: Toward improved interoperability of distributed biological databases, an increasing number of datasets have been published in the standardized Resource Description Framework (RDF). Although the powerful SPARQL Protocol and RDF Query Language (SPARQL) provides a basis for exploiting RDF...

Cite
Chiba H, Uchiyama I. SPANG: a SPARQL client supporting generation and reuse of queries for distributed RDF databases. BMC Bioinformatics. 2017;18(1):93doi: 10.1186/s12859-017-1531-1.
Chiba, H., & Uchiyama, I. (2017). SPANG: a SPARQL client supporting generation and reuse of queries for distributed RDF databases. BMC bioinformatics, 18(1), 93. https://doi.org/10.1186/s12859-017-1531-1
Chiba, Hirokazu, and Uchiyama, Ikuo. "SPANG: a SPARQL client supporting generation and reuse of queries for distributed RDF databases." BMC bioinformatics vol. 18,1 (2017): 93. doi: https://doi.org/10.1186/s12859-017-1531-1
Chiba H, Uchiyama I. SPANG: a SPARQL client supporting generation and reuse of queries for distributed RDF databases. BMC Bioinformatics. 2017 Feb 08;18(1):93. doi: 10.1186/s12859-017-1531-1. PMID: 28178937; PMCID: PMC5299738.
Copy Download .nbib Format: NLM
Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis.

Oncotarget

Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N.
PMID: 29545925
Oncotarget. 2018 Feb 03;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20.

BACKGROUND: Interferon-free treatment can achieve higher sustained virological response (SVR) rates, even in patients in whom hepatitis C virus (HCV) could not be eradicated in the interferon treatment era. Immune restoration in the liver is occasionally associated with HCV...

Cite
Kanda T, Yasui S, Nakamura M, et al. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018;9(14):11631-11637doi: 10.18632/oncotarget.24391.
Kanda, T., Yasui, S., Nakamura, M., Nakamoto, S., Takahashi, K., Wu, S., Sasaki, R., Haga, Y., Ogasawara, S., Saito, T., Kobayashi, K., Kiyono, S., Ooka, Y., Suzuki, E., Chiba, T., Maruyama, H., Imazeki, F., Moriyama, M., & Kato, N. (2018). Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget, 9(14), 11631-11637. https://doi.org/10.18632/oncotarget.24391
Kanda, Tatsuo, et al. "Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis." Oncotarget vol. 9,14 (2018): 11631-11637. doi: https://doi.org/10.18632/oncotarget.24391
Kanda T, Yasui S, Nakamura M, Nakamoto S, Takahashi K, Wu S, Sasaki R, Haga Y, Ogasawara S, Saito T, Kobayashi K, Kiyono S, Ooka Y, Suzuki E, Chiba T, Maruyama H, Imazeki F, Moriyama M, Kato N. Interferon-free treatment for patients with chronic hepatitis C and autoimmune liver disease: higher SVR rates with special precautions for deterioration of autoimmune hepatitis. Oncotarget. 2018 Feb 03;9(14):11631-11637. doi: 10.18632/oncotarget.24391. eCollection 2018 Feb 20. PMID: 29545925; PMCID: PMC5837765.
Copy Download .nbib Format: NLM
Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits.

Oncotarget

Yoshida T, Ri M, Kanamori T, Aoki S, Ashour R, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Kitahata S, Chiba T, Ichikawa S, Iida S.
PMID: 29515784
Oncotarget. 2018 Jan 11;9(11):9975-9991. doi: 10.18632/oncotarget.24160. eCollection 2018 Feb 09.

Proteasome inhibitors (PI), mainly targeting the β5 subunit of the 20S proteasome, are widely used in the treatment of multiple myeloma (MM). However, PI resistance remains an unresolved problem in the therapy of relapsed and refractory MM. To develop...

Cite
Yoshida T, Ri M, Kanamori T, et al. Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits. Oncotarget. 2018;9(11):9975-9991doi: 10.18632/oncotarget.24160.
Yoshida, T., Ri, M., Kanamori, T., Aoki, S., Ashour, R., Kinoshita, S., Narita, T., Totani, H., Masaki, A., Ito, A., Kusumoto, S., Ishida, T., Komatsu, H., Kitahata, S., Chiba, T., Ichikawa, S., & Iida, S. (2018). Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits. Oncotarget, 9(11), 9975-9991. https://doi.org/10.18632/oncotarget.24160
Yoshida, Takashi, et al. "Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits." Oncotarget vol. 9,11 (2018): 9975-9991. doi: https://doi.org/10.18632/oncotarget.24160
Yoshida T, Ri M, Kanamori T, Aoki S, Ashour R, Kinoshita S, Narita T, Totani H, Masaki A, Ito A, Kusumoto S, Ishida T, Komatsu H, Kitahata S, Chiba T, Ichikawa S, Iida S. Potent anti-tumor activity of a syringolin analog in multiple myeloma: a dual inhibitor of proteasome activity targeting β2 and β5 subunits. Oncotarget. 2018 Jan 11;9(11):9975-9991. doi: 10.18632/oncotarget.24160. eCollection 2018 Feb 09. PMID: 29515784; PMCID: PMC5839415.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 1673 entries